Active-ingredient Dossier
Erlotinib Hydrochloride
Active-ingredient Dossier for Erlotinib Hydrochloride (tyrosine kinase inhibitor). Australian brands, products, PBS listings, PBAC outcomes — compiled by…
- Brand: ERLOTINIB ARX
- Brand: ERLOTINIB SANDOZ
- Brand: ERLOTINIB CIPLA
- Brand: CIPLOTINIB
- Brand: ERLOCIP
- Therapeutic area: Oncology
What is
Erlotinib Hydrochloride Erlotinib Hydrochloride is a tyrosine kinase inhibitor.
Australian brands containing
Erlotinib Hydrochloride — ERLOTINIB ARX — ERLOTINIB CIPLA — ERLOTINIB SANDOZ — CIPLOTINIB — ERLOCIP
Therapeutic areas
Erlotinib Hydrochloride is registered in oncology, with 5 brands containing this ingredient on the ARTG.
Sponsor landscape
The ingredient is marketed by three sponsors: Cipla, Accelagen and Sandoz.
PBS and regulatory activity
One brand containing erlotinib hydrochloride has a PBS-listed item, with the latest PBS schedule date of 1 May 2026. The latest PBAC outcome is 1 November 2014, with one brand having PBAC outcomes on record. No brands have AusPARs on record.